Get 40% Off
🚨 Volatile Markets? Find Hidden Gems for Serious Outperformance
Find Stocks Now

Earnings Call: Sensient Technologies Reports Q3 2023 Results, Expects Improvement in 2024

Published 23/10/2023, 08:44 pm
© Reuters.

Sensient Technologies Corporation (NYSE: NYSE:SXT) reported a decrease in local currency revenue and adjusted EBITDA in its third-quarter earnings conference call. The company attributed the decline to customer destocking and lower volumes in the Color Group while noting gradual improvements in the Flavors Group. Despite these challenges, Sensient remains optimistic about its long-term growth prospects, forecasting volume improvements in the fourth quarter and into the first quarter of 2024.

Key takeaways from the call:

  • Sensient Technologies reported a single-digit decrease in local currency revenue and a 7% decrease in local currency adjusted EBITDA.
  • The company anticipates volume improvements in Q4 2023 and Q1 2024, attributing the decline to customer destocking and lower volumes in the Color Group.
  • The company is focusing on winning new business, managing cost inflation, and optimizing its cost structure.
  • Capital expenditures for Q3 2023 were $22.6 million, with total expected capital expenditures for the year around $85 million.
  • Sensient expects 2023 local currency revenue to be up low single digits compared to 2022, and 2023 local currency EPS to be down low double digits compared to 2022 adjusted EPS of $3.29.
  • The company is optimistic about new product wins and expects to see improvement in 2024, with destocking no longer being a major headwind.

During the call, Sensient CEO Paul Manning discussed the company's strategic investment in natural ingredients within the flavors and extracts group. He also addressed the recent ban on Red Dye No. 3 in California, stating that while not a significant source of revenue for Sensient, it opens up opportunities for natural colors, aligning with the company's focus on natural alternatives.

3rd party Ad. Not an offer or recommendation by Investing.com. See disclosure here or remove ads .

Manning also noted the uncertain impact of GLP-1, a drug that reduces calorie consumption, on Sensient's business, stating that it depends on factors such as adoption rate and economic viability. Despite the uncertainties, the company is prepared to adapt to different segments and product lines.

The company also reported receiving more urgent orders from customers, indicating a potential over-aggressive destocking. However, Sensient's efficient service levels have resulted in shorter lead times, albeit making forecasting more challenging. The company expects this trend of larger in-month orders to continue and anticipates improved performance in 2024.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.